CN103120763A - Medicinal composition for treating sequela of cerebral apoplexy - Google Patents
Medicinal composition for treating sequela of cerebral apoplexy Download PDFInfo
- Publication number
- CN103120763A CN103120763A CN2011103687106A CN201110368710A CN103120763A CN 103120763 A CN103120763 A CN 103120763A CN 2011103687106 A CN2011103687106 A CN 2011103687106A CN 201110368710 A CN201110368710 A CN 201110368710A CN 103120763 A CN103120763 A CN 103120763A
- Authority
- CN
- China
- Prior art keywords
- parts
- cerebral apoplexy
- treatment
- radix
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicinal composition for treating sequela of cerebral apoplexy. The medicinal composition consists of astragalus, pseudo-ginseng root, szechuan lovage rhizome, erigeron breviscapine, tall gastrodia tuber, scorpio, medicinal cyathula root, borneol and other Chinese herbal materials, has the effects of tonifying qi, activating blood and eliminating blood stasis, is clinically applied to treatment of sequela of cerebral apoplexy for many years and has an obvious curative effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of cerebral apoplexy sequela, more specifically say a kind of and have QI invigorating, invigorate blood circulation, the effect of blood stasis dispelling; Be used for the treatment of leave over after apoplexy more such as hemiplegia, facial hemiparalysis, the sequela such as handicapped.Belong to field of medicaments.
Background technology
Apoplexy is apoplexy (Stroke) in modern medicine, be a kind of cerebral blood circulation obstacle disease of unexpected onset.Clinical manifestation take suddenly flutter dusk, syncope or occur suddenly that facial hemiparalysis, hemiplegia, stiff tongue speech are not smoothgoing, dysnoesia is as principal character.
At present, Chinese and western medicine has the measure of reasonable Therapeutic Method for suffering from acute stroke, can effectively control development and the continuity of apoplexy.But often after disease was sent out two weeks, it is very not obvious that therapeutic effect all seems.Morbidity substantially be can't see obvious symptom during 1-6 month and is taken on a new look, and fall therefrom that the arm lower limb is ineffective, patient presents " carrying the basket sample on the arm " action, lower limb are stiff as post, are distinctive " drawing a circle " gait, deflective mouth and eye, hemiplegia stiff tongue speech during walking not smoothgoing etc. lifelong disabled.And its relapse rate is also very high.Therefore, apoplexy sequela can be rated as global difficult medical problem.After entering convalescent period, often do not control for many doctors.
The inventor tries to explore and sums up the treatment rule of cerebral apoplexy sequela in a large amount of clinical practices.On the basis in accordance with the traditional treatment rule for the treatment of, invented medicine of the present invention in conjunction with patient's body constitution and disease incidence characteristics and rule, clinical practice for many years, many many effect for the treatment of sequela of apoplexy are remarkable.
Summary of the invention
Purpose of the present invention just is to provide a kind of pharmaceutical composition for the treatment of cerebral apoplexy sequela, and this pharmaceutical composition has QI invigorating, invigorates blood circulation, the effect of blood stasis dispelling, is used for clinically cerebral apoplexy sequela.
For achieving the above object, the pharmaceutical composition for the treatment of cerebral apoplexy sequela provided by the invention is prepared from by the processing of the crude drug of following weight parts:
Radix Astragali 100-200 part Radix Notoginseng 80-120 part Rhizoma Chuanxiong 30-50 part Herba Erigerontis 60-100 part
Rhizoma Gastrodiae 30-50 part Scorpio 5-10 part Radix Cyathulae 20-40 part Borneolum Syntheticum 3-5 part.
Preferred version is prepared from by the processing of the crude drug of following weight parts:
80 parts of 40 parts of Herba Erigerontiss of 100 parts of Rhizoma Chuanxiongs of 150 portions of Radix Notoginseng of the Radix Astragali
4 parts of 30 parts of Borneolum Syntheticums of 8 portions of Radix Cyathulaes of 40 portions of Scorpios of Rhizoma Gastrodiae.
The pharmaceutical composition for the treatment of cerebral apoplexy sequela of the present invention can be prepared into any clinical applicable dosage form in pill, capsule, tablet, granule, oral liquid.
Described weight portion can be the weight metering units such as gram, two, jin, kilogram, ton.
Pharmaceutical composition of the present invention can adopt the ingredients of conventional method in writing out a prescription to carry out in proportion compatibility, makes various clinical applicable dosage forms by existing preparation process, and ingredients used is the Chinese crude drug that commercially available process is up to the standards.
Why the present invention selects above-mentioned medical material as raw material, is because they have following effect:
The Radix Astragali: invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.Be used for the deficiency of vital energy weak, anorexia and loose stool, sinking of QI of middle-JIAO, the chronic diarrhea proctoptosis, the metrorrhagia of having blood in stool, the exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle is difficult bursts, and burst for a long time and do not hold back, the blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst; Chronic nephritis proteinuria, diabetes.
Radix Notoginseng: dissipating blood stasis hemostasis, subduing swelling and relieving pain.Be used for spitting of blood, spit blood, epistaxis is had blood in stool, metrorrhagia, and traumatic hemorrhage, the breast abdomen twinges, tumbling and swelling.
Rhizoma Chuanxiong: blood-activating and qi-promoting, wind-expelling pain-stopping.Be used for menoxenia, amenorrhea dysmenorrhea, abdominal mass stomachache, the twinge of the breast side of body, tumbling and swelling, headache, rheumatic arthralgia.
Herba Erigerontis: can distend the blood vessels, blood flow volume increases, peripheral vascular resistance reduces, and can be used for apoplexy sequela (paralysis), Ischemic Stroke, rheumatalgia, stomachache, toothache, flu, osteomyelitis etc.
Rhizoma Gastrodiae: suppressing the hyperactive liver to relieve the wind syndrome relieving convulsion.Be used for having a headache dizzy, numb limbs and tense tendons, infantile convulsion, epilepsy clonus, tetanus disease.
Scorpio: endogenous wind stopping spasmolytic, dispersing pathogen accumulation, removing obstruction in the collateral to relieve pain.Be used for infantile convulsion, tic spasm, middle air port, hemiplegia, tetanus disease, rheumatoid arthritis stubborn, migraine and general headache, skin infection, scrofula.
Radix Cyathulae: eliminating blood stasis and inducing menstruation, easing joint movement, inducing diuresis for treating stranguria syndrome.Be used for the amenorrhea lump in the abdomen, retention of placenta, arthralgia, flaccidity of the lower limbs clonic spasm of the muscle, hematuria stranguria with blood, injury from falling down.
Borneolum Syntheticum: the refreshment of having one's ideas straightened out, clearing away heat to alleviate pain.Faint for calentura coma, convulsion, the apoplexy syncope due to accumulation of phlegm, the stagnation of QI is sudden and violent
Faint, the attacked by pestiferous factors stupor, conjunctival congestion, aphtha, laryngopharynx swelling and pain, auditory meatus is suppurated.
Pharmaceutical composition provided by the invention has QI invigorating, invigorates blood circulation, the effect of blood stasis dispelling; Be used for the treatment of clinically cerebral apoplexy sequela.
Therapeutic effect of the present invention proves with following case:
Medical record for example
Case: Zhang, female, 76 years old.In November, 2009, Zhang trikes cerebral infarction, and the hands neck feels like jelly, and mouth is askew, walks not Cheng Lu, eats the drink mouth and don't work.Clothes for patients is used medicine of the present invention more than 30 days, and one day pair is now fully recovered.Mouth is not askew, speaks clearly, can get up, and chat can trot out, drop in.
The specific embodiment
Below with embodiment, a kind of pharmaceutical composition for the treatment of cerebral apoplexy sequela of the present invention is further described; this will help the present invention and effect thereof are further understood; embodiment does not limit protection scope of the present invention, and its protection domain is decided by claim.
Embodiment 1
60 parts of 30 parts of Herba Erigerontiss of 80 parts of Rhizoma Chuanxiongs of 100 portions of Radix Notoginseng of the Radix Astragali
3 parts of 20 parts of Borneolum Syntheticums of 5 portions of Radix Cyathulaes of 30 portions of Scorpios of Rhizoma Gastrodiae
Embodiment 2
100 parts of 50 parts of Herba Erigerontiss of 120 parts of Rhizoma Chuanxiongs of 200 portions of Radix Notoginseng of the Radix Astragali
5 parts of 40 parts of Borneolum Syntheticums of 10 portions of Radix Cyathulaes of 50 portions of Scorpios of Rhizoma Gastrodiae
Embodiment 3
80 parts of 40 parts of Herba Erigerontiss of 100 parts of Rhizoma Chuanxiongs of 150 portions of Radix Notoginseng of the Radix Astragali
4 parts of 30 parts of Borneolum Syntheticums of 8 portions of Radix Cyathulaes of 40 portions of Scorpios of Rhizoma Gastrodiae
Above-mentioned composition is in the application for the treatment of cerebral apoplexy sequela.
Above-mentioned composition can be made any existing clinical applicable dosage form in pill, capsule, tablet, granule, oral liquid according to prior art.
Claims (3)
1. pharmaceutical composition for the treatment of cerebral apoplexy sequela is characterized in that being prepared from by the crude drug processing of following weight parts:
Radix Astragali 100-200 part Radix Notoginseng 80-120 part Rhizoma Chuanxiong 30-50 part Herba Erigerontis 60-100 part
Rhizoma Gastrodiae 30-50 part Scorpio 5-10 part Radix Cyathulae 20-40 part Borneolum Syntheticum 3-5 part.
2. a kind of pharmaceutical composition for the treatment of cerebral apoplexy sequela according to claim 1 is characterized in that being prepared from by the crude drug processing of following weight parts:
80 parts of 40 parts of Herba Erigerontiss of 100 parts of Rhizoma Chuanxiongs of 150 portions of Radix Notoginseng of the Radix Astragali
4 parts of 30 parts of Borneolum Syntheticums of 8 portions of Radix Cyathulaes of 40 portions of Scorpios of Rhizoma Gastrodiae.
3. one of them described a kind of pharmaceutical composition for the treatment of cerebral apoplexy sequela according to claim 1 and 2, is characterized in that, preparation is any existing clinical applicable dosage form in pill, capsule, tablet, granule, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103687106A CN103120763A (en) | 2011-11-20 | 2011-11-20 | Medicinal composition for treating sequela of cerebral apoplexy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103687106A CN103120763A (en) | 2011-11-20 | 2011-11-20 | Medicinal composition for treating sequela of cerebral apoplexy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103120763A true CN103120763A (en) | 2013-05-29 |
Family
ID=48452030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103687106A Pending CN103120763A (en) | 2011-11-20 | 2011-11-20 | Medicinal composition for treating sequela of cerebral apoplexy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103120763A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104324250A (en) * | 2014-11-06 | 2015-02-04 | 中国人民解放军第四军医大学 | Traditional Chinese medicine composition for cerebral arterial thrombosis and preparation method of traditional Chinese medicine composition |
| CN105878769A (en) * | 2014-10-08 | 2016-08-24 | 马中杰 | Medicine formula for preventing cerebral infarction and treating stroke sequelae |
-
2011
- 2011-11-20 CN CN2011103687106A patent/CN103120763A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878769A (en) * | 2014-10-08 | 2016-08-24 | 马中杰 | Medicine formula for preventing cerebral infarction and treating stroke sequelae |
| CN104324250A (en) * | 2014-11-06 | 2015-02-04 | 中国人民解放军第四军医大学 | Traditional Chinese medicine composition for cerebral arterial thrombosis and preparation method of traditional Chinese medicine composition |
| CN104324250B (en) * | 2014-11-06 | 2018-09-04 | 中国人民解放军第四军医大学 | A kind of cerebral arterial thrombosis Chinese medicine composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104826016B (en) | A kind of pharmaceutical composition and its preparation method and application for treating the proliferation of mammary gland | |
| CN103083433B (en) | Drug for treating rheumatism and rheumatoid sciatica | |
| CN104027684A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN103120763A (en) | Medicinal composition for treating sequela of cerebral apoplexy | |
| CN101647924A (en) | Traditional Chinese medicine formula for treating chronic pelvic inflammation in oral-taking way | |
| WO1999025368A1 (en) | A medicine for treating algomenorrhea and the method of preparation thereof | |
| CN104623376B (en) | Be used for the treatment of prosopalgic medicine | |
| CN103120738A (en) | Medicinal composition for treating ischemic cerebral apoplexy | |
| CN105250427A (en) | Pharmaceutical composition for treating heart diseases | |
| CN102600351B (en) | Traditional Chinese medicine for treating pruritus cutanea | |
| CN104337989A (en) | Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout | |
| CN103735647A (en) | Medicated wine for treating chronic infectious arthritis | |
| CN103735907A (en) | Traditional Chinese medicine for treating facial neuritis | |
| CN103585414B (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
| CN106377619A (en) | Pharmaceutical composition for treating polycystic ovarian syndrome | |
| CN106421538A (en) | Traditional Chinese medicine miniature enema for treating chronic pelvic inflammatory disease | |
| CN103120735A (en) | Medicinal composition for treating cerebral apoplexy hemiplegia | |
| CN101983666A (en) | Traditional Chinese medicine composition for treating rheumatism and preparation method thereof | |
| CN102743550B (en) | Medicine composition for accelerating healing after fracture surgery, preparation method and application | |
| CN105194427A (en) | Traditional Chinese medicine composition for treating xerophthalmia and preparation method of traditional Chinese composition | |
| CN110478416A (en) | The composition and its preparation method and application for treating rheumatic rheumatoid arthritis | |
| CN103845456A (en) | Medicament for treating cerebrovascular hemiplegia | |
| CN103961490A (en) | Compound medicine for treating wind-cold-dampness arthralgia and preparation method thereof | |
| CN105561266A (en) | Traditional Chinese medicine composition for treating acute cholecystitis and application thereof | |
| CN102805803B (en) | Traditional Chinese medicine for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130529 |